Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Borneol/edaravone - Simcere

Next Previous
X
Search
Drug Profile

Borneol/edaravone - Simcere

Alternative Names: Compound edaravone; Edaravone combination; Edaravone Dexborneol; Edaravone/borneol; Sanbaxin®; Sanbexin; SIM 071201

Latest Information Update: 09 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroDawn; Simcere Pharmaceutical Group
  • Developer Simcere Pharmaceutical Group
  • Class Antidementias; Heterocyclic bicyclo compounds; Neuroprotectants; Pyrazolones; Small molecules; Terpenes; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stroke
  • New Molecular Entity No

Highest Development Phases

  • Marketed Stroke
  • Phase II Cerebral haemorrhage
  • No development reported Cerebrovascular disorders

Most Recent Events

  • 05 Sep 2024 Borneol/edaravone - Simcere receives Breakthrough Therapy status for Stroke in USA
  • 21 May 2024 The National Medical Products Administration (NMPA) accepts NDA for Stroke (Sublingual, Tablet) for review
  • 18 Mar 2024 Simcere Pharmaceutical plans phase-II trial for Cognition disorders (In adults, In the elderly) in China (Sublingual, Tablet) in March 2024 (NCT06315231),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top